润都股份(002923.SZ):预计2025年亏损6000万元–7800万元

Core Viewpoint - Rundu Co., Ltd. (002923.SZ) expects a loss of 60 million to 78 million yuan in 2025, with a non-recurring loss of 70 million to 88 million yuan due to various factors affecting performance [1] Group 1: Financial Performance - The company anticipates a significant loss in 2025, with projected figures indicating a loss between 60 million and 78 million yuan [1] - The non-recurring loss is expected to range from 70 million to 88 million yuan [1] Group 2: Reasons for Performance Change - The primary reason for the performance change is the ongoing implementation of the national drug procurement policy, which has led to a year-on-year decline in the gross profit margin of major formulation products [1] - Intense competition in both domestic and international markets has resulted in further price declines for certain raw material intermediates, contributing to a decrease in the consolidated gross profit margin of these intermediates [1] - The company has disposed of some production lines for non-core products, impacting overall performance [1]

Rundu Pharma-润都股份(002923.SZ):预计2025年亏损6000万元–7800万元 - Reportify